Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma
- Conditions
- Lymphoma
- Registration Number
- NCT00098332
- Lead Sponsor
- BioCryst Pharmaceuticals
- Brief Summary
RATIONALE: Forodesine (BCX-1777) may stop the growth of cancer cells by blocking the enzymes necessary for their growth.
PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory stage IIA, stage IIB, stage III, stage IVA, or stage IVB cutaneous T-cell lymphoma.
- Detailed Description
OBJECTIVES:
* Determine the safety and efficacy of forodesine (BCX-1777) in patients with refractory stage IIA-IVB cutaneous T-cell lymphoma.
* Determine the pharmacokinetics and pharmacodynamics of this drug in these patients.
OUTLINE: This is an open-label, multicenter study.
Patients receive oral forodesine (BCX-1777) once daily on days 1-28. Courses may be repeated in the absence of disease progression or unacceptable toxicity.
Patients are followed periodically.
PROJECTED ACCRUAL: Not specified.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (10)
Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham
🇺🇸Birmingham, Alabama, United States
Burke Pharmaceutical Research
🇺🇸Hot Springs, Arkansas, United States
Stanford Comprehensive Cancer Center - Stanford
🇺🇸Stanford, California, United States
University of Colorado Cancer Center at UC Health Sciences Center
🇺🇸Aurora, Colorado, United States
Yale Cancer Center
🇺🇸New Haven, Connecticut, United States
Cancer and Blood Disease Center
🇺🇸Lecanto, Florida, United States
Dana-Farber/Brigham and Women's Cancer Center
🇺🇸Boston, Massachusetts, United States
Duke Comprehensive Cancer Center
🇺🇸Durham, North Carolina, United States
Charles M. Barrett Cancer Center at University Hospital
🇺🇸Cincinnati, Ohio, United States
M.D. Anderson Cancer Center at University of Texas
🇺🇸Houston, Texas, United States
Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham🇺🇸Birmingham, Alabama, United States